Leading the Science
In Inflammation Drug Discovery
Targeting Chronic Inflammation
to Treat Neurodegeneration and Inflammatory Diseases by Inhibiting the Activity of the NLRP3 Inflammasome
At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system’s response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
Founded in 2017, our incredible team of scientists has worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.
In The News
The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being...
Starting a company is interesting. I’m a scientist by training and have often considered myself the world’s most...
Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical...
We Are Experienced in Drug Discovery for Oncology and Neurodegeneration
Our scientists have made fundamental discoveries in the fields of oncology, Alzheimer’s disease, and other neurodegenerative disorders, and we leverage these experiences to identify novel targets to treat these diseases.
- Oral Systemic Multiple Indications 90% 90%
- Ophthalmology 50% 50%
- Gastroenterology 50% 50%
- Neuroinflammation 40% 40%
- Dermatology 30% 30%
- Intervertebral Disc Disease 30% 30%
- Alzheimer's Disease 50% 50%
- Parkinson's Disease 50% 50%